Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate.
BACKGROUND
Retroviral involvement in amyotrophic lateral sclerosis (ALS) has been suspected for several years since the recognition that both murine and human retroviruses can cause ALS-like syndromes. Nonquantitative studies have demonstrated the retroviral enzyme reverse transcriptase (RT) in ALS patients' sera, but the amount and source of RT activity are unknown. We therefore developed a quantitative assay to study RT levels in ALS and examined the possibility that the recently discovered human gammaretrovirus XMRV (xenotropic MuLV-related virus) might be the source of the RT activity.


METHODS
A quantitative product-enhanced RT assay was used to measure RT activity levels in serum and CSF. XMRV sequences were sought by PCR analysis of DNA and RNA extracted from blood.


RESULTS
Fifty percent of ALS patients' sera contained >6 x 10(-8) RT units/mL as opposed to 7% of control sera (p = 0.008). The levels of RT activity in ALS patients were comparable to the levels observed in patients infected with HIV. RT activity was detected in only 1 of 25 CSF samples tested. XMRV sequences were not found in any of 25 nucleic acid extracts obtained from ALS patients' blood.


CONCLUSIONS
These findings further support the concept of retroviral involvement in amyotrophic lateral sclerosis (ALS) and demonstrate that serum is more suitable than CSF for assay of reverse transcriptase (RT) activity in this disease. The levels of serum RT activity detected are comparable to those found in HIV infection. XMRV is not detectable in the blood of ALS patients, and the agent responsible for ALS-associated RT activity therefore remains unidentified.
McCormick
A L
AL
Centre for Virology, Department of Infection, University College London, London, UK.
Brown
R H
RH
Cudkowicz
M E
ME
Al-Chalabi
A
A
Garson
J A
JA
D000690:Amyotrophic Lateral Sclerosis / Q000201:enzymology / Q000235:genetics* / Q000821:virology*; D001681:Biological Assay / Q000379:methods; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D002490:Central Nervous System / Q000378:metabolism / Q000503:physiopathology / Q000821:virology; D017988:Gammaretrovirus / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D009046:Motor Neurons / Q000378:metabolism / Q000473:pathology / Q000821:virology; D011237:Predictive Value of Tests; D012194:RNA-Directed DNA Polymerase / Q000032:analysis* / Q000097:blood / Q000134:cerebrospinal fluid; D012192:Retroviridae Infections / Q000150:complications* / Q000201:enzymology / Q000235:genetics*; D019562:Viral Load; D017735:Virus Latency / Q000235:genetics
D015415:Biomarkers; D012194:RNA-Directed DNA Polymerase